Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021
Weekly / July 23, 2021 / 70(29);1022–1023
Meghan Lyman, MD1; Kaitlin Forsberg, MPH1; Jacqueline Reuben, MHS2; Thi Dang, MPH3; Rebecca Free, MD1; Emma E. Seagle, MPH1; D. Joseph Sexton, PhD1; Elizabeth Soda, MD4; Heather Jones, DNP4; Daryl Hawkins, MSN2; Adonna Anderson, MSN2; Julie Bassett, MPH3; Shawn R. Lockhart, PhD1; Enyinnaya Merengwa, MD, DrPH3; Preetha Iyengar, MD2; Brendan R. Jackson, MD1; Tom Chiller, MD1 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
Candida auris is an emerging, often multidrug-resistant yeast that is highly transmissible, resulting in health care–associated outbreaks, especially in long-term care facilities. Skin colonization with C. auris allows spread and leads to invasive infections, including bloodstream infections, in 5%–10% of colonized patients (1). Three major classes of antifungal medications exist for treating invasive infections: azoles (e.g., fluconazole), polyenes (e.g., amphotericin B), and echinocandins. Approximately 85% of C. auris isolates in the United States are resistant to azoles, 33% to amphotericin B, and 1% to echinocandins (2), based on tentative susceptibility breakpoints.* Echinocandins are thus critical for treatment of C. auris infections and are recommended as first-line therapy for most invasive Candida infections (3). Echinocandin resistance is a concerning clinical and public health threat, particularly when coupled with resistance to azole and amphotericin B (pan-resistance).
Pan-resistant C. auris isolates have been reported previously, although rarely, from the United States (4) and other countries (5). Three pan-resistant C. auris cases reported in New York developed resistance following echinocandin treatment and lacked epidemiologic links or common health care (4), suggesting that resistance resulted from antifungal pressure rather than via person-to-person transmission. Since January 2021, however, the Antibiotic Resistance Laboratory Network has detected independent clusters of pan-resistant or echinocandin-resistant cases in Texas and the District of Columbia (DC). Each cluster involved common health care encounters and no known previous echinocandin exposure, suggesting transmission of pan- and echinocandin-resistant strains for the first time in the United States.
Among 101 clinical and screening cases of C. auris† in DC during January–April 2021, three had an isolate that was pan-resistant. All resistant isolates were identified through skin colonization screening at one long-term care facility for severely ill patients, including those requiring mechanical ventilation.
Among 22 clinical and screening cases of C. auris in Texas during the same period, two were pan-resistant and five were resistant to both echinocandins and fluconazole. These seven cases were identified in patients who were cared for at two facilities that share patients in the same city; two patients were at a long-term acute care hospital, three at a short-term acute care hospital, and two at both facilities. Among these cases, four were identified through colonization screening and three through clinical isolates (two blood isolates and one wound isolate).
No known epidemiologic links were identified between the Texas and DC clusters. No patients with pan- or echinocandin-resistant isolates in either cluster had received echinocandins before C. auris specimen collection. Thirty-day mortality in both outbreaks combined was 30%, but the relative contribution of C. auris was unclear.
These two simultaneous, independent clusters of pan- or echinocandin-resistant C. auris cases in patients with overlapping inpatient health care exposures and without previous echinocandin use provide the first evidence suggesting that pan- or echinocandin-resistant C. auris strains might have been transmitted in U.S. health care settings. Surveillance, public health reporting, and infection control measures are critical to containing further spread. Clinicians should consider early antifungal susceptibility testing in patients with C. auris infection, especially in those with treatment failure. Data are lacking about the most appropriate therapy for pan-resistant infections. Combination and investigational antifungal treatments can be considered, but evidence in clinical settings is limited (6). More information is needed to evaluate patient outcomes and identify proper treatment for C. auris cases with pan-resistance or echinocandin resistance.
Corresponding author: Meghan Lyman, firstname.lastname@example.org, 404-639-4241.
1Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 2Center for Policy Planning and Evaluation, DC Health, Washington, DC; 3Texas Department of State Health Services; 4Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Thi Dang reports a position as an unpaid member of the Board of Directors of the Dallas/Fort Worth Chapter of the Association for Professionals in Infection Control and Epidemiology. No other potential conflicts of interest were disclosed.
- Southwick K, Adams EH, Greenko J, et al. New York State 2016–2018: progression from Candida auris colonization to bloodstream infection. Open Forum Infect Dis 2018;5(Suppl 1):S594–5. https://doi.org/10.1093/ofid/ofy210.1695external icon
- Forsberg K, Lyman M, Chaturvedi S, et al. Public health action-based system for tracking and responding to U.S. Candida drug resistance: AR Lab Network, 2016–2019. Open Forum Infect Dis 2020;7(Suppl 1):S206–7. https://doi.org/10.1093/ofid/ofaa439.465external icon
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1–50. https://doi.org/10.1093/cid/civ933external icon PMID:26679628external icon
- Ostrowsky B, Greenko J, Adams E, et al.; C. auris Investigation Work Group. Candida auris isolates resistant to three classes of antifungal medications—New York, 2019. MMWR Morb Mortal Wkly Rep 2020;69:6–9. https://doi.org/10.15585/mmwr.mm6901a2external icon PMID:31917780external icon
- Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017;64:134–40. https://doi.org/10.1093/cid/ciw691external icon PMID:27988485external icon
- O’Brien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe 2020;1:e193–4. https://doi.org/10.1016/S2666-5247(20)30090-2external icon
Suggested citation for this article: Lyman M, Forsberg K, Reuben J, et al. Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021. MMWR Morb Mortal Wkly Rep 2021;70:1022–1023. DOI: http://dx.doi.org/10.15585/mmwr.mm7029a2external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to email@example.com.